Injectable thermosensitive hydrogels delivering resveratrol demonstrate significant cartilage protection in mouse osteoarthritis models by activating SIRT1 and suppressing HIF1α nuclear translocation, ultimately reducing MMP13-mediated cartilage breakdown. The temperature-sensitive gel allows precise intra-articular delivery while maintaining sustained release properties. This research bridges longevity science with orthopedic medicine by leveraging resveratrol's SIRT1 activation—the same pathway linked to cellular aging and lifespan extension—for joint preservation. The finding suggests longevity compounds may have broader therapeutic applications beyond their traditional anti-aging context. While promising, this represents early-stage research in animal models, and the clinical translation remains uncertain. Joint degeneration affects millions of aging adults, making effective cartilage protection strategies critically important for healthspan. The thermosensitive delivery system could overcome resveratrol's notorious bioavailability issues that have limited its therapeutic potential. However, the inflammatory IL-1β model used may not fully recapitulate complex human osteoarthritis pathophysiology. This work represents incremental but meaningful progress in both drug delivery innovation and our understanding of how longevity pathways influence musculoskeletal health.